Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$81.19

4.09 (5.30%)

08:15
10/02/18
10/02
08:15
10/02/18
08:15

Seattle Genetics price target raised to $98 from $90 at RBC Capital

RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $98 and kept his Outperform rating, saying its ECHELON-2 trial "exceeded best case scenario" with a "surprise" overall survival benefit. The analyst notes that the results were a "clean win with E-2's magnitude of PFS benefit", raising his probability of success for the program to 100% from 75%.

SGEN Seattle Genetics
$81.19

4.09 (5.30%)

10/01/18
PIPR
10/01/18
NO CHANGE
Target $71
PIPR
Neutral
Seattle Genetics positive data already priced into shares, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro believes the positive Phase III Echelon-2 trial announced this morning by Seattle Genetics "was fully baked into" the shares. The analyst remains comfortable with his Adcetris estimates pending the full data and keeps a Neutral rating on the shares with a $71 price target. The stock in early trading is up 3%, or $2.00, to $79.12.
09/26/18
JPMS
09/26/18
NO CHANGE
Target $85
JPMS
Overweight
Seattle Genetics price target raised to $85 from $77 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Seattle Genetics to $85 saying he's bullish on the potential success of ECHELON-2, which is expected to readout in Q4. The analyst, however, thinks expectations from investors are "relatively high." Nevertheless, another successful readout and material line extension for Adcetris could help maintain the stock's "impressive recent momentum," Kasimov tells investors in a research note. He keeps an Overweight rating on Seattle Genetics.
09/24/18
LEER
09/24/18
INITIATION
Target $101
LEER
Outperform
Seattle Genetics initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started Seattle Genetics with an Outperform rating and $101 price target.
09/17/18
GUGG
09/17/18
INITIATION
Target $90
GUGG
Buy
Seattle Genetics initiated with a Buy at Guggenheim
Target $90.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.